Rating 4.8

2,400 reviews

Zepbound® is Eli Lilly's brand of tirzepatide, approved for chronic weight management. What it costs you depends almost entirely on one thing: whether your insurance plan covers it. With coverage and a manufacturer savings card, the monthly cost can fall to a copay. Without coverage, you are looking at the manufacturer's self-pay channel, a cash price at a pharmacy, or the list price, and those three numbers are very far apart.

This page sets out the real price points, what moves them and where each current figure is published, then covers how the medication works, how to dose and inject it, and how it differs from Mounjaro®, which contains the same active ingredient. Society does not dispense Zepbound. What Society does offer instead, and how it differs, is set out plainly further down this page.

Five routes, five very different numbers. Third-party figures below are approximate and current as of September 2026, and each row names the channel that publishes the live one.

Why the spread is this wide. The list price is a reference number discounts are negotiated against, not a real-world cost. Manufacturer self-pay pricing exists precisely because so many plans exclude weight management drugs. And a telehealth price is a different product from a pharmacy price: it bundles the visit, the prescription, the dose management and the shipping.

One practical point about strength. Novo Nordisk's list price for Wegovy is the same across its strengths, so if your own cost jumps when your dose goes up, the change is coming from your plan's deductible or tier logic rather than from the medication. Society's Wegovy listing spans doses from 0.25 mg to 7.2 mg, and which strength is right for you is a prescriber's decision, not a shopping choice.

Is Wegovy covered by insurance? Sometimes, and it is the single biggest variable in your cost. Many commercial plans cover it with a prior authorization that requires a documented BMI threshold and often a period of supervised lifestyle intervention. Many others exclude weight management medication as a category. Our insurance page sets out how to check and what a prior authorization usually asks for.

Manufacturer direct self-pay. Novo Nordisk operates a cash-pay pharmacy channel, NovoCare Pharmacy, at a price far below the list price. It has been reset more than once since 2024, so read the current figure there rather than one you saw quoted elsewhere. You still need a valid prescription, and self-pay pricing generally cannot be combined with an insurance claim.

Pharmacy cash price with a discount card. Prices vary between pharmacies, sometimes by a lot. Call several.

Telehealth with the treatment plan included. Society's brand Wegovy pricing starts at $1,695 per month and includes the consultation, labs, shipping and ongoing management. The honest comparison is against a pharmacy price plus a separate office visit and labs, and even then it is the more expensive option.

A different medication. Zepbound® contains tirzepatide rather than semaglutide and is also approved for chronic weight management. Plans that exclude one sometimes cover the other. Society does not dispense Zepbound, but our Zepbound page sets out what it costs through every route that does.

A compounded option. Society also offers personalized compounded semaglutide, prescribed by a licensed US practitioner for a specific patient's needs, from $149 per month. Compounded medications are not FDA-approved and have not been evaluated by the Food and Drug Administration for safety, efficacy, or quality, and a compounded formulation is not the same product as Wegovy and is not equivalent to it. Whether one is appropriate is a clinical decision, not a menu choice. Our compounded versus brand GLP-1 page sets out exactly how the rules governing this route have narrowed.

Wegovy is prescription-only, so an online route still runs through a licensed clinician. What changes is the logistics. You complete a medical intake covering height, weight, medical history, current medications, allergies and any personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. A US-licensed clinician reviews it and consults with you, synchronously or asynchronously depending on your state. If Wegovy is clinically appropriate, the prescription goes to a licensed pharmacy that ships to you, and follow-up visits handle escalation and side effects.

Two things to check before you hand over a card. The service should name the licensed prescriber who will see you and the pharmacy that will dispense. And the medication should be identified specifically: "brand Wegovy" and "semaglutide" are not interchangeable descriptions, and a price far below the numbers in the table above is not brand Wegovy.

What the price includes. A personalized treatment plan, the medication, labs, expedited shipping and continuous clinical assistance, with free discreet delivery in 1 to 2 days and no insurance required. Most members hear back from a provider within a day or two, more than 10,000 patients have been treated, and support typically replies within 24 hours. You can pause, switch or cancel anytime, and the first two months of any treatment plan are strictly non-refundable. Providers are licensed in the state where the patient is located at the time of consultation, so availability may vary by state.

Wegovy contains semaglutide, a GLP-1 receptor agonist. GLP-1 is a hormone your gut releases after you eat. Semaglutide is built to imitate it, but to last far longer in the body, which is what makes once-weekly dosing possible.

Appetite and food intake. Semaglutide acts on areas of the brain that regulate appetite and reward. Most people describe eating less because they want less, rather than because they are resisting more.

Gastric emptying. Food leaves the stomach more slowly, so fullness lasts longer after a meal. This is also the source of most of the gastrointestinal side effects.

Insulin and glucagon. Insulin secretion increases when blood glucose is high, and glucagon falls. This is the diabetes mechanism, and it operates here too.

Wegovy comes in five strengths, all given once weekly by subcutaneous injection: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg. This is the escalation schedule in the prescribing information.

When to increase your Wegovy dose
‍
Every four weeks, on your prescriber's instruction, following the schedule above. The four-week interval is not arbitrary: it exists to let gastrointestinal tolerance build before the next step.

The schedule bends where it needs to. If you are struggling with side effects at a given step, the prescribing information allows delaying the increase by four weeks rather than pushing through. If you cannot tolerate 2.4 mg, 1.7 mg once weekly can be used as the maintenance dose. Neither of those is a failure, and neither is something to decide alone: tell your prescriber what is actually happening and let them adjust.

Missed doses. If you miss a dose and your next scheduled dose is more than two days (48 hours) away, take the missed dose as soon as you can. If it is less than two days away, skip it and take the next one on your normal day. Do not double up.

Wegovy is injected subcutaneously, into the fat layer just under the skin. Three sites are approved: the abdomen, which is the most commonly used, the front of the upper thigh, and the back of the upper arm. Rotate the site each week, do not use the same exact spot two weeks running, and avoid skin that is tender, bruised, red, hard or scarred. You do not need to change site to change dose, and the site does not need to match your previous week.

The Wegovy pen is a single-dose autoinjector with a hidden needle. One pen delivers one weekly dose and is then discarded.

Always follow the Instructions for Use supplied with your pen. Device designs change, and the instructions in the box are the ones that apply to you. Our general injection guide covers technique in more detail.

Storage. Keep Wegovy in the refrigerator at 36°F to 46°F (2°C to 8°C) in the original carton to protect it from light. It can be kept at room temperature, between 46°F and 86°F (8°C to 30°C), for up to 28 days if needed. Do not freeze it, and do not use a pen that has been frozen.

Wegovy is FDA approved, which means FDA judged its benefits to outweigh its risks for the populations described on its label. It also carries a boxed warning, which is the strongest warning FDA applies.

Boxed warning: risk of thyroid C-cell tumors. In rodent studies, semaglutide caused thyroid C-cell tumors. It is not known whether it causes these tumors, including medullary thyroid carcinoma, in humans. Wegovy must not be used by anyone with a personal or family history of medullary thyroid carcinoma (MTC), or by anyone with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Do not use Wegovy if you have had a serious allergic reaction to semaglutide or any of its ingredients, or if either boxed warning condition applies. Tell your prescriber if you are pregnant, planning pregnancy or breastfeeding.

Serious risks in the prescribing information include pancreatitis, gallbladder problems including gallstones, low blood sugar (particularly with insulin or a sulfonylurea), serious allergic reactions, acute kidney injury from dehydration, worsening of diabetic retinopathy in people with type 2 diabetes, increased heart rate, depression or thoughts of suicide, and food remaining in the stomach during general anesthesia or deep sedation, which you must disclose to any surgeon or anesthesiologist before a procedure.

The most common side effects are nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, indigestion, dizziness, abdominal distension, burping, flatulence, gastroenteritis and heartburn (Novo Nordisk, Wegovy prescribing information). This is a summary, not the full label. Read the complete prescribing information and medication guide, and our Wegovy safety information.

Does Wegovy make you tired?
‍
Yes, fatigue is a recognized side effect. It is listed among the common adverse reactions in the Wegovy prescribing information and was reported more often by participants taking semaglutide than by those on placebo. It is usually most noticeable in the first weeks and after each dose increase, and it usually eases.

The likely contributors are worth knowing because most of them are addressable: eating substantially less, which produces tiredness on its own; dehydration, because appetite suppression tends to reduce fluid intake as well as food intake; low protein intake, which is easy to slip into when you are not hungry; poor sleep from gastrointestinal symptoms, particularly reflux at night; and low blood sugar, which is mainly a risk if you also take insulin or a sulfonylurea.

Practical steps: keep fluids up deliberately rather than by thirst, prioritize protein in the meals you do eat, and do not cut calories below what your clinician has set. Fatigue that is severe, that does not improve after the first few weeks, or that comes with dizziness, a racing heart or shortness of breath should be reported to your clinician rather than absorbed.

Rybelsus®. Novo Nordisk sells oral semaglutide as Rybelsus, a daily tablet. Rybelsus is approved to improve blood sugar control in adults with type 2 diabetes. It is not approved for chronic weight management, and it is dosed completely differently from Wegovy.

Oral semaglutide at weight-management strengths. A daily semaglutide tablet dosed for chronic weight management is a separate product from both Wegovy and Rybelsus, with its own label, strengths and price. Neither the strengths nor the price carry over from the injection, so Novo Nordisk's product pages and your prescriber are where to establish what is currently available to you.

One thing settles the question here: Society currently offers injectable GLP-1 medication only. There is no oral or tablet GLP-1 in its range at any price. Metformin, which Society offers from $99 per month, is oral but is not a GLP-1 and works by a different mechanism.

If you are looking for an oral option because you do not want to inject, say that to your prescriber directly. It is a common and entirely reasonable preference, and it is worth discussing before you settle on a medication.

Supply is not the constraint it was. FDA declared the semaglutide shortage resolved in February 2025, and the Wegovy supply picture has broadly normalized since. Stock gaps now tend to be local and short rather than national and sustained. If your pharmacy does not have your strength:

Ask them to order it. Most gaps are a restocking interval, not a shortage.

Call other pharmacies nearby, including the ones inside grocery and big-box stores, which often hold different inventory from standalone chains.

Use the manufacturer's direct pharmacy channel, which ships to you and does not depend on local retail inventory.

Check the FDA Drug Shortages database for current national status rather than a news article or a forum post, both of which date quickly.

Ask your prescriber about a strength adjustment if a specific pen is genuinely unavailable. That is a clinical decision, not a substitution to make yourself.

Brand Wegovy from $1,695 per month, with the treatment plan, labs, expedited shipping and continuous clinical assistance included. A licensed US practitioner decides whether it is right for you before anything is prescribed.

* Individual results may vary, and not all patients will qualify for treatment. Always consult a licensed healthcare provider before starting or modifying any medical treatment.

Society facilitates access to consultations with independent, licensed healthcare providers who evaluate each patient and determine eligibility for treatment. Prescription products require an online medical evaluation. Medications are prescribed by independent physicians and dispensed by licensed U.S. pharmacies or a patient's preferred pharmacy. Only a qualified healthcare provider can determine whether a treatment is appropriate for an individual's specific medical needs.
Providers are licensed in the state where the patient is located at the time of consultation, and availability may vary by state.
Society's services are intended for individuals 18 years of age or older. Age verification may be required as part of the intake process.
‍Society partners with licensed U.S. pharmacies. Certain treatments may include compounded medications, which are not FDA-approved and have not been evaluated by the Food and Drug Administration for safety, efficacy, or quality. Compounded medications may be prescribed by a healthcare provider based on individual patient needs or during periods of drug shortages. FDA-approved GLP-1 medications—such as Ozempic® (semaglutide), Wegovy® (semaglutide), and Zepbound® (tirzepatide)—are not compounded. Society is not affiliated with, endorsed by, or sponsored by the manufacturers of these products. All trademarks and brand names belong to their respective owners.
GLP-1–based treatments may carry risks, including the potential for thyroid C-cell tumors. These medications should not be used by individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Please consult a healthcare provider for complete prescribing and safety information.
Prescription medications are dispensed only when determined appropriate by a licensed healthcare provider following an online medical evaluation. No prescription is guaranteed, and treatment decisions are made solely at the prescriber's clinical discretion.
Statements on this website have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Images shown are for illustrative purposes only; actual product appearance may vary.